Cargando…

1402. Expand accessibility of monoclonal antibody in COVID-19 among different ethnicities and races.

BACKGROUND: Anti-SARS-CoV-2 monoclonal antibodies are administered to patients with mild-moderate COVID-19 who are at high risk of progression to severe disease. It has been shown that in addition to medical comorbidities, race or ethnicity may also place patients at high risk for progression to sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooq, Hina, Shankaran, Shivanjali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752574/
http://dx.doi.org/10.1093/ofid/ofac492.1231

Ejemplares similares